scPharmaceuticals Inc. (NASDAQ:SCPH) Q4 2022 Earnings Conference Call March 22, 2023 4:30 PM ET

Company Participants

PJ Kelleher - LifeSci Advisors

John Tucker - CEO

Rachael Nokes - CFO

Steve Parsons - SVP, Commercial

Conference Call Participants

Glen Santangelo - Jefferies

Nik Gasic - SVB Securities

Stacy Ku - Cowen

Douglas Tsao - H.C. Wainwright

Nazibur Rahman - Maxim Group

Greetings, and welcome to the scPharmaceuticals Fourth Quarter and Full Year 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, PJ Kelleher, LifeSci Advisors. Thank you, Peter. PJ, you may begin.

PJ Kelleher

Thank you, operator. Before turning the call over to management, I would like to make the following remarks concerning forward-looking statements. All statements on this conference call, other than historical facts, are forward-looking statements within the meaning of the federal securities laws including, but not limited to statements regarding scPharmaceuticals' expected future financial results; and management's expectations and plans for the business and FUROSCIX.

The words anticipate, believe, estimate, expect, intend, guidance, confidence, target, project and other similar expressions are typically used to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and may involve and are subject to certain resins and uncertainties and other important factors that may affect business, financial condition and other operating results. These include, but are not limited to, the risk factors and other qualifications contained in scPharmaceuticals' annual report on Form 10-K, quarterly reports on Form 10-Q and other reports filed by the company with the SEC to which your attention is directed. Actual outcomes and results may differ materially from what is expressed or implied by these forward-looking statements.

Any forward-looking statements made in this conference call, including responses to your questions, are based on current expectations as of today, and scPharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

It is now my pleasure to turn the call over to Mr. John Tucker, Chief Executive Officer of scPharmaceuticals. John?

John Tucker

Thank you, PJ, and thank you to, everyone, listening to this afternoon's call and webcast.

This afternoon, I am pleased to provide an operational update on the initial stages of the FUROSCIX commercial launch before I turn the call over to Rachael Nokes, our newly appointed Chief Financial Officer for a review of our financials.